Five Year Survival Study Evaluating the Genesis Dental Implant System (Genesis Dental)

April 5, 2012 updated by: Keystone Dental, Inc.

Clinical Analysis of a Biomimetic Implant System: Five Year Survival Rates, Marginal Bone-level Changes, and Soft Tissue Aesthetics.

The purpose of this research study is to document the use if the Keystone Dental Genesis Dental Implant System in standard clinical use and to provide 5 year survival data.

Study Overview

Status

Unknown

Conditions

Detailed Description

The technology behind dental implants is well established and the Genesis Dental Implant System has been cleared for marketing by the FDA. It is Keystone Dental's choice to collect post-market data within the framework of a clinical trial in order to assess the clinical performance of this device.

The risks of the Genesis Dental Implant System are no different than other comparable dental implant systems currently in use. Keystone Dental expects the clinical performance of this device to be equal to that of comparable implant systems.

The purpose of this research study is to assess the 5 year survival rate of the Genesis Dental Implant System, as well as assess the safety and effectiveness endpoints, which include incidence of adverse effects, change in bone height and soft tissue aesthetic outcomes.

Study Type

Observational

Enrollment (Anticipated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Newport Beach, California, United States, 92660
        • Newport Coast Oral Facial Institute
      • Woodland Hills, California, United States, 91367
        • Brighton Periodontal & Implant Dental Group
    • Illinois
      • Oakbrook Terrace, Illinois, United States, 60181
        • Periodontal Medicine & Surgical Specialists, LTD
    • Maryland
      • Baltimore, Maryland, United States, 21209
        • Kevin G. Murphy & Associates, PA
    • New York
      • New York, New York, United States, 10155
        • Specialized Dentistry of New York
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19102
        • Edwin Rosenberg, DMD, HDD, BDS
    • Texas
      • Houston, Texas, United States, 77042
        • PerioHealth Professionals, PLLC
    • Virginia
      • Gainesville, Virginia, United States, 20155
        • Dental Design

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Subjects between the ages of 18 and 85 who require dental implants

Description

Inclusion Criteria:

  • Subject must be between 18 and 85 years old, inclusive, and have passed growth maximum at the time of implant placement
  • Subject must be willing to sign the informed consent document and adhere to study procedures.
  • Subject must have one or more natural teeth missing or about to be extracted.
  • Subject must fulfill all the accepted medical and dental requirements for treatment with dental implants.
  • Subject must desire treatment with dental implants.

Exclusion Criteria:

  • Subject refuses to sign the informed consent document.
  • Subject's treatment success by both clinical and esthetic measures may be compromised by the restricted range of product available for the study.
  • The treatment plan to use the range of products available is not in the best interests of the subject. Please see Section 1.2.1 for restrictions on product availability.
  • The implant site(s) had a previously failed implant.
  • Subject cannot be treated within the restrictions of the treatment plan laid out in Section 5. In addition, please see Section 1.2.1 for restrictions on product availability.
  • Subject with alveolar ridge dimensions that are not sufficient to accommodate and sustain proper implant placement.
  • Subject is not communicable in an understandable language.
  • Current Alcohol or Drug Abuse (within previous 12 months) as noted in the subject's chart.
  • Women who are pregnant at time of enrollment in to the study.
  • Subject with out of control metabolic disease.
  • Subject who have been on chemotherapy or long term cortisone use (at any time).
  • Subject with known allergy to titanium.
  • Subject with diabetes.
  • Subject with a history of autoimmune disease (e.g. documented multiple allergies, systemic lupus erythematosus, dermatomyositis, etc.) or immunosuppressive disease (e.g. human immunodeficiency virus or acquired immunodeficiency syndrome).
  • Subject with epilepsy.
  • Subjects with uncontrolled or severe cases of hyperthyroidism, malignancies, renal disease, liver problems, hypertension, leukemia, severe vascular heart disease, hepatitis, collagen and bone diseases, or other serious illnesses.
  • Subject currently taking bisphosphonate or calcium channel blockers.
  • There is reasonable doubt that the subject will comply with the recall schedule.
  • There is reasonable doubt that the subject will comply with the clinicians' instructions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dennis Tarnow, DDS, Specialized Dentistry of New York

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (Anticipated)

March 1, 2017

Study Completion (Anticipated)

July 1, 2017

Study Registration Dates

First Submitted

April 4, 2012

First Submitted That Met QC Criteria

April 5, 2012

First Posted (Estimate)

April 6, 2012

Study Record Updates

Last Update Posted (Estimate)

April 6, 2012

Last Update Submitted That Met QC Criteria

April 5, 2012

Last Verified

April 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • KD-CR 02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dental Implants

3
Subscribe